Novavax COVID-19 vaccine shows 90.4% efficacy in late stage trial
Novavax Inc on Monday (June 14) reported late-stage data from its U.S.-based clinical trial showing its vaccine is more than 90% effective against COVID-19 across a variety of variants of the virus.
The study of nearly 30,000 volunteers in the United States and Mexico puts Novavax on track to file for emergency authorization in the United States and elsewhere in the third quarter of 2021, the company said.
Novavax’s protein-based COVID-19 vaccine candidate was more than 93% effective against the predominant variants of COVID-19 that have been of concern among scientists and public health officials, Novavax said.
Protein-based vaccines are a conventional approach that uses purified pieces of the virus to spur an immune response and vaccines again whooping cough and shingles employ this approach.